ibandronic acid has been researched along with Low Bone Density in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ishimoto, T; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M | 1 |
| Ishimoto, T; Matsugaki, A; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M | 1 |
| Abualhamael, SA; Baig, M; Malik, AA; Shahzad, M; Tariq, S | 1 |
| Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L | 1 |
| Adamidou, F; Anagnostis, P; Charizopoulou, M; Garipidou, V; Goulis, DG; Karagiannis, A; Karras, S; Vakalopoulou, S; Vyzantiadis, TA | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 1 |
| Baek, HJ; Choe, JY; Kang, SW; Lee, SG; Lee, YJ; Park, SH; Park, W; Park, YB; Shin, K; Song, JS; Song, YW; Yoo, B; Yoo, DH; Yoo, WH | 1 |
| Bachmann, G; Bonnick, SL; Civitelli, R; Kohles, JD; Martens, M; Silverman, S; Tanner, SB | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Armbrecht, G; Beller, G; Bock, O; Börst, H; Degner, C; Felsenberg, D; Martus, P; Roth, HJ | 1 |
| Chapurlat, RD; de Vernejoul, MC; Delmas, PD; Laroche, M; Rouanet, S; Thomas, T | 1 |
| Lo, JC; O'Ryan, FS | 1 |
| Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G | 1 |
| Dobrokhotov, IV; Durnova, GN; Il'ina-Kakueva, EI; Kaplanskiĭ, AS; Larina, IM; Morukov, BV | 1 |
| Bauss, F; Eberhardt, C; Kurth, AH; Müller, S; Schwarz, M; Steinacker, M | 1 |
| Lipton, A | 1 |
| De Broe, M; Ketteler, M; Persy, V | 1 |
| Barrett, J; Gieschke, R; Goggin, T; Pillai, G; Steimer, JL; Worth, E | 1 |
| Baumann, M; Christensen, JO; Clemmesen, B; Ravn, P | 1 |
2 review(s) available for ibandronic acid and Low Bone Density
| Article | Year |
|---|---|
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
7 trial(s) available for ibandronic acid and Low Bone Density
| Article | Year |
|---|---|
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method | 2019 |
The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Hemophilia A; Hemophilia B; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors | 2013 |
Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Bone Diseases, Metabolic; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Peptides | 2017 |
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; X-Ray Microtomography | 2012 |
Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Radius; Tibia; Tomography, X-Ray Computed | 2013 |
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
Topics: Adult; Aged; Area Under Curve; Asian People; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Collagen Type I; Creatinine; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Peptides; Postmenopause; Retrospective Studies; Sex Factors; Tissue Distribution; White People | 2006 |
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Follow-Up Studies; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Peptides; Spine | 1998 |
12 other study(ies) available for ibandronic acid and Low Bone Density
| Article | Year |
|---|---|
Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae.
Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Elastic Modulus; Endocrine System Diseases; Estrogens; Ibandronic Acid; Osteoporosis; Rats; Spine | 2022 |
Combination treatment with ibandronate and eldecalcitol prevents osteoporotic bone loss and deterioration of bone quality characterized by nano-arrangement of the collagen/apatite in an ovariectomized aged rat model.
Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Collagen; Estrogens; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Vitamin D | 2022 |
Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females.
Topics: Bone Diseases, Metabolic; Case-Control Studies; Female; Humans; Ibandronic Acid; Osteoprotegerin; Polymorphism, Single Nucleotide; Postmenopause | 2023 |
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires | 2009 |
Pricey osteoporosis remedy doesn't beat older drugs.
Topics: Advertising; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Dietary; Diphosphonates; Drug Costs; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Vitamin D | 2009 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Cohort Studies; Debridement; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Ibandronic Acid; Male; Middle Aged; Osteolysis; Osteoporosis; Osteosclerosis; Retrospective Studies; Tooth Extraction; Treatment Outcome; Wound Healing | 2012 |
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chi-Square Distribution; Cholecalciferol; Creatinine; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Femur Neck; Fractures, Bone; Germany; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
[Effects of ibandronate on the osteopenia process in tail-suspended rats].
Topics: Adrenal Glands; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Data Interpretation, Statistical; Diphosphonates; Hindlimb Suspension; Ibandronic Acid; Male; Rats; Thymus Gland; Tibia; Time Factors; Weightlessness | 2003 |
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Durapatite; Female; Femur; Ibandronic Acid; Osseointegration; Osteoporosis; Ovariectomy; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Titanium | 2005 |
Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcinosis; Diphosphonates; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Mice; Rats; Vascular Diseases | 2006 |